

1 Title:

2 **Single-Cell Genomics Identifies Cell Type-Specific**

3 **Molecular Changes in Autism**

4 Short title: Single-cell Analysis of Autism

5 Authors:

6 Dmitry Velmeshev<sup>1,2‡</sup>, Lucas Schirmer<sup>1,3,4</sup>, Diane Jung<sup>1,2</sup>, Maximilian Haeussler<sup>5</sup>, Yonatan  
7 Perez<sup>1,2</sup>, Simone Mayer<sup>1,2</sup>, Aparna Bhaduri<sup>1,2</sup>, Nitasha Goyal<sup>1,2,6</sup>, David H. Rowitch<sup>1,3,7,8</sup> and  
8 Arnold R. Kriegstein<sup>1,2‡</sup>

9 Affiliations:

10 <sup>1</sup>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San  
11 Francisco, San Francisco, CA 94143, USA; <sup>2</sup>Department of Neurology, University of California, San Francisco, San  
12 Francisco, CA 94158, USA; <sup>3</sup>Department of Pediatrics, University of California, San Francisco, CA 94143, USA;  
13 <sup>4</sup>Department of Neurology, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany,  
14 <sup>5</sup>Genomics Institute, University of California, Santa Cruz, <sup>6</sup>Department of Molecular and Cell Biology, University of  
15 California, Berkeley, <sup>7</sup>Department of Paediatrics and Wellcome Trust-MRC Cambridge Stem Cell Institute,  
16 University of Cambridge, Cambridge, CB20QQ, UK; <sup>8</sup>Department of Neurosurgery, University of California, San  
17 Francisco, San Francisco, CA 94143, USA; ‡-corresponding author.

1 Abstract:

2 **Despite the clinical and genetic heterogeneity of autism, bulk gene expression studies show**  
3 **that changes in the neocortex of autism patients converge on common genes and pathways.**  
4 **However, direct assessment of specific cell types in the brain affected by autism has not been**  
5 **feasible until recently. Here we utilize single-nucleus RNA sequencing of cortical tissue from**  
6 **patients with autism to identify autism-associated transcriptomic changes in specific cell**  
7 **types. We find that synaptic signaling of upper-layer excitatory neurons and the molecular**  
8 **state of microglia are preferentially affected in autism. Moreover, we demonstrate that**  
9 **dysregulation of specific groups of genes in cortico-cortical projection neurons correlates**  
10 **with clinical severity of autism. These findings suggest that molecular changes in upper-layer**  
11 **cortical circuits are linked to behavioral manifestations of autism.**

12 One Sentence Summary:

13 Single-cell analysis categorizes cell types most affected by autism molecular pathology and  
14 changes correlated with clinical severity.

15


1     **TEXT**

2     Autism spectrum disorder (ASD) affects 1 of 59 children in the US. Although bulk transcriptomic  
3     tissue studies revealed convergence of disease pathology on common pathways (1-3), the cell type-  
4     specific molecular pathology of ASD is unclear. We aimed to gain insight into cell-type specific  
5     transcriptomic changes by performing unbiased single-nucleus RNA sequencing (snRNA-seq) (4)  
6     of 41 post-mortem tissue samples including prefrontal (PFC) and anterior cingulate (ACC) cortical  
7     regions from 15 ASD patients and 16 controls (**Fig. 1A**, data S1). Samples in the control and ASD  
8     groups were between four and 22 years old and matched for age, sex, RNA integrity number (RIN),  
9     and post-mortem interval (fig. S1A;  $p > 0.1$ , Mann–Whitney U test). None of the ASD patients were  
10    diagnosed with intellectual disability; however, half of ASD patients had a history of seizures, a  
11    common co-morbidity in ASD. To compare changes in ASD to those in patients with sporadic  
12    epilepsy only, we generated additional snRNA-seq data from eight PFC samples from patients  
13    with sporadic epilepsy and seven age-matched controls (data S1).

14    We processed tissue samples for nuclei isolation and snRNA-seq using the 10x Genomics platform  
15    (**Fig. 1B**). We generated 104,559 single-nuclei gene expression profiles; 52,556 from control  
16    subjects and 52,003 from ASD patients (data S2), and detected a median of 1,391 genes and 2,213  
17    transcripts per nucleus, a yield that is in agreement with a recent snRNA-seq study (5). Numbers  
18    of genes and transcripts were uniform between control and ASD (fig. S1B). Additionally, we  
19    generated 21,984 single-nuclei profiles sampled from patients with epilepsy and controls.  
20    Multiplet nuclei capture rate was comparable to single-cell RNA-seq analysis using the 10x  
21    platform (fig. S1C). The libraries were sequenced to 86% average saturation (fig. S1D; data S1).

22    We next performed unbiased clustering of nuclear profiles from ASD and control samples

1 combining both cortical regions (**Fig. 1C**). Clustering was not driven by experimental batch or  
 2 individual samples (fig. S1E). We annotated clusters based on expression of known cell type  
 3 markers (data S3) and identified 11 neuronal and six glial cell types, including subtypes of  
 4 excitatory neurons, interneurons (**Fig. 1, D to F**), and astrocytes (**Fig. 1G**). We observed that  
 5 neurons expressed more genes and transcripts than glia (fig. S1F). Certain cell types, such as layer  
 6 4 excitatory neurons, were enriched in one of the two cortical regions (fig. S1G), and there were  
 7 relatively more protoplasmic astrocytes in ASD samples (fig. S1, H to I; fig. S2, A to C). Clustering  
 8 was consistent when cells with high UMI counts were removed (fig. S2 D and E), or when using  
 9 Seurat to perform clustering (fig. S2 F and G). We validated the increased density of protoplasmic  
 10 astrocytes and confirmed expression of markers for NRGN neurons and subtypes of astrocytes  
 11 using *in situ* RNA hybridization (fig. S3, A to D).



12


1 **Fig. 1. Overview of the experimental approach and snRNA-seq dataset.**

2 **A)** Cortical regions analyzed with snRNA-seq including the PFC and ACC regions. **B)** Experimental  
3 approach to snap-frozen tissue sample processing and nuclei isolation. **C)** Unbiased clustering of snRNA-  
4 seq data. Cell types were annotated based on expression of known marker genes. **D)** Expression of  
5 excitatory neuronal subtype markers. **E)** Inhibitory neuronal subtype marker expression. **F)** Markers of  
6 neurogranin (NRGN)-expressing neurons. **G)** Markers of glial cell types and endothelial cells.

7 We tested whether our findings were representative of observations from bulk sequencing studies  
8 by performing whole-tissue RNA isolation and sequencing. Bulk gene expression changes in our  
9 ASD patient cohort correlated with fold changes from a published RNA-seq dataset (3) (fig. S3E).  
10 We found a significant number of common differentially expressed genes (DEGs) based on our  
11 bulk RNA-seq analysis (fig. S3F). We calculated whole-tissue nuclear RNA expression by  
12 aggregating all single-nuclei profiles in each sample. When nuclear RNA levels were correlated  
13 with mRNA levels across all samples, we observed a positive correlation for 93% and a significant  
14 correlation for 37% of genes (Pearson's  $r \geq 0.31$ ,  $p < 0.05$ ) (fig. S3G).

15 To identify genes dysregulated in ASD in a cell type-specific manner, we compared nuclear  
16 profiles from ASD and control subjects for each cell type using a linear mixed model (LMM)  
17 (Materials and Methods). We detected 692 differential expression events ( $q$  value  $< 0.05$ ;  
18 expression level change  $\geq 10\%$ ) in 513 unique DEGs. 79% (407 out of 513) of DEGs were  
19 differentially expressed in a single cell type (data S4). Gene expression changes were of smaller  
20 magnitude than expected based on bulk RNA-seq, potentially due to drop-out events. Only 17%  
21 of DEGs were specific to a single cell type, suggesting cell type-specific dysregulation of  
22 ubiquitously expressed genes. Top differentially expressed neuronal genes were downregulated in

1 L2/3 excitatory neurons and VIP-expressing interneurons (**Fig. 2A**). Top genes differentially  
2 expressed in non-neuronal cell types were upregulated in protoplasmic astrocytes and microglia  
3 (**Fig. 2B**). We analyzed the intersection between our gene list and the list of 851 genes that have  
4 evidence of genetic association with ASD from the SFARI database (6). Out of 513 DEGs genes,  
5 75 (13%) were found in the SFARI database ( $p=1.9 \times 10^{-17}$ , hypergeometric test) (fig. S3H),  
6 including 26 top SFARI genes (**Fig. 2C**). Additionally, we found significant overlap with high-  
7 confidence ASD-associated genetic risk factors (7, 8) (**Fig. 2D**, fig. S3I). SFARI genes were most  
8 overrepresented in L2/3 and L4 excitatory neurons, followed by VIP and SST interneurons (**Fig.**  
9 **2E**). Gene Ontology (GO) analysis demonstrated that chemical synaptic transmission, axon  
10 guidance, neuronal migration, and GABA signaling were among the top dysregulated pathways  
11 (**Fig. 2F**). We observed enrichment in similar GO terms when only neuronal DEGs were used (fig.  
12 S4A), but no GO terms were identified for glial DEGs, suggesting convergence on the same  
13 cellular pathways in neuronal but not glial cells types. Similar pathways were enriched for DEGs  
14 with high nuclear/mRNA correlation (**Fig. 2, G to H**), and DEGs common to several cell types  
15 were associated with the development of neuronal projections and adhesion (fig. S4B). By  
16 downsampling the data to compare the same number of nuclei across all cell types, we found that  
17 L2/3 excitatory neurons had the largest number of DEGs (**Fig. 2I**) followed by L4 excitatory  
18 neurons and microglia. The number of DEGs did not correlate significantly with the number of  
19 genes expressed in a given cell type (Pearson's  $r=0.27$ ,  $p=0.3$ ). Thus, our results point to  
20 enrichment of ASD molecular changes in cellular components of upper layer cortical circuits.




**Figure 2. Cell type-specific gene expression changes in ASD.**

**A-B**) Volcano plots for cell type-specific genes differentially expressed in neuronal (**A**) and non-neuronal cells (**B**). **C**) Overlap between DEGs and top ASD genetic risk factors from the SFARI database (gene scores 1-3 and syndromic). **D**) Overlap between cell type-specific DEGs and high-confidence ASD genetic risk factors based on whole exome sequencing (35,584 ASD subjects). **E**) Overlap between SFARI genes and DEGs; Dashed line indicates statistical significance ( $q < 0.05$ ). **F**) Top biological pathways enriched for DEGs identified across all analyzed cell types. Stacked bars represent numbers of up- and downregulated genes in each GO term. **G**) Correlation between mRNA and nuclear RNA for DEGs in same tissue samples. **H**) GO analysis for DEGs with significant mRNA/nuclear RNA correlation. **I**) Burden analysis on downsampled data. P values were calculated by comparing numbers of DEGs between cell types (Mann-Whitney U Test).

We then investigated specific gene expression changes in neuronal (**Fig. 3A**) and glial subtypes.

1 Hierarchical clustering of cell types based on fold changes of gene expression between ASD and  
2 control (**Fig. 3B**) revealed that cell types clustered based on developmental lineages. Among the  
3 top genes dysregulated in L2/3 and L4 neurons, we observed genes important for synaptic function,  
4 such as *STX1A*, *SYN2* and *NRXN1*, as well as the transcription factors *TCF25*, *SOX5* and *RBFOX3*  
5 crucial for brain development (**Fig. 3, C to D**). *TCF25* was also downregulated in VIP  
6 interneurons, as was the transcription factor *AH11* and the synaptic gene *RAB3A* (fig. S4C).  
7 Microglia from ASD samples were enriched for genes associated with activation and  
8 transcriptional factors regulating developmental processes (fig. S4D). We observed similar  
9 dysregulation of developmental transcription factors in protoplasmic astrocytes, as well as  
10 upregulation of cell motility (fig. S4E). Deconvolution of bulk transcriptomic data from ASD  
11 patients (**Supplementary Text**) suggested that astrocytes in ASD are in an activated state and  
12 dysregulate genes necessary for amino acid transport (fig. S4, F to G). A number of genes were  
13 dysregulated in a region-dependent manner (fig. S4H; data S4) and were enriched in processes  
14 associated with neuron differentiation and cell migration (**Fig. 3E**). These included genes in L2/3,  
15 L4 neurons (**Fig. 3, F to G**), and interneurons (fig. S4I). Overall, our data point to dysregulated  
16 development and synaptic signaling in components of upper-layer cortical circuitry, as well as the  
17 cellular state of microglia and protoplasmic astrocytes.





**Figure 3. Gene expression changes across specific cell types in ASD.**


**A)** Schematic of cortical neurons with known layer localization. Color boxes refer to cell types identified in Figure 1C. **B)** Hierarchical clustering based on log-transformed fold changes of DEGs in each cell type. **C)** Violin plots for top genes differentially expressed in ASD in L2/3 neurons. Genes dysregulated in sporadic epilepsy are indicated in orange. Fold changes (ASD/Control) indicated under gene names. **D)** Violin plots for top genes differentially expressed in L4 neurons in ASD. **E)** GO analysis of genes differentially expressed specifically in PFC and ACC. **F-G)** Examples of top region-specific DEGs dysregulated in L2/3 and L4. Star denotes statistically significant change in gene expression between ASD and CNTR in either the PFC or ACC.

We next tested whether cell type-specific changes correlated with the clinical severity of ASD. We obtained Autism Diagnostic Interview-Revised (ADI-R) scores that measured impairment of behavioral domains in ASD (**Fig. 4A**). We correlated patient ADI-R scores with fold changes of DEGs and observed that changes in L2/3 neurons and microglia were the most predictive of

1 clinical severity (**Fig. 4B**). We found that patients with different degrees of clinical severity  
2 clustered based on dysregulation of L2/3 neuron and microglia DEGs (**Fig. 4C to D**). Interestingly,  
3 genes most correlated with clinical severity (fig. S5, A to B) were not among the top ASD DEGs,  
4 suggesting that degree of dysregulation is not an accurate predictor of correlation with clinical  
5 symptoms. We next compared single-cell profiles from individual ASD patients to control profiles  
6 across all clusters to identify cell types that are recurrently affected across multiple patients (**Fig.**  
7 **4E**; fig. S5, C to D). These included upper (L2/3) and deep layer (L5/6-CC) cortico-cortical  
8 projection neurons, while cortico-fugal L5/6 projection neurons were not enriched in ASD DEGs.  
9 These results highlight the convergence of ASD-associated changes on cortico-cortical projection  
10 neurons across layers. Furthermore, whole-exome sequencing identified potentially deleterious  
11 genetic variants that correlated with reduced expression of corresponding genes (data S5)  
12 suggesting a potential link between genomic variations and transcriptional dysregulation in  
13 individual ASD patients.

14 Since epilepsy is often a co-morbidity of ASD, we analyzed shared and divergent molecular  
15 changes in ASD and sporadic epilepsy. We analyzed snRNA-seq data from PFC samples from  
16 eight epilepsy patients and seven matched controls (fig. S6, A-C). We found that epilepsy shared  
17 only 10% of all identified cell type-specific gene expression changes we observed in ASD,  
18 including 20% of the genes dysregulated in L2/3 neurons (fig. S6D-F). GO analysis of DEGs  
19 detected in ASD, but not epilepsy, identified synaptic transmission, axon guidance, and brain  
20 development as enriched pathways (fig. S6G). Changes associated with epilepsy co-morbidity in  
21 the ASD group were enriched in L5/6 cortico-fugal projection neurons and parvalbumin  
22 interneurons (fig S6H). Therefore, the majority of molecular changes and core dysregulated  
23 pathways we identify in ASD samples are the result of primary ASD pathogenesis and not seizure

1 activity.



2  
3 **Figure 4. Correlation of cell type-specific gene dysregulation in ASD patients with clinical severity.**

4 **A)** Strategy for correlating individual-level DEGs and clinical severity. ADI-R sub-scores were ranked and  
5 combined. ASD cases were compared to the combined control profiles in each cell type to generate  
6 individual fold changes. **B)** Cell types ranked by correlation of DEGs with combined clinical scores. Cell-  
7 type DEGs in green significantly correlated with clinical severity. **C-D)** Hierarchical clustering of ASD  
8 patients based on individual fold changes in gene expression level in L2/3 neurons **(C)** and microglia **(D)**.  
9 Average clinical scores, prevalence of epilepsy, and non-verbal subjects, age and gender composition are  
10 provided below the heatmaps. **E)** Analysis of cell types most enriched for transcriptional changes in  
11 individual ASD patients.

12 Previous studies suggested convergence of ASD on specific cell types during fetal development  
13 (9, 10). We find that cell types with shared developmental lineages exhibit convergent  
14 transcriptional changes in adult ASD patients, and that expression of synaptic and

1 neurodevelopmental genes in layer 2/3 cortical neurons are especially affected. This implies that  
2 disturbances of gene regulatory programs during development cascade into molecular pathology  
3 in specific mature neural cell types.

4 We find that specific sets of genes enriched in upper-layer projection neurons and microglia  
5 correlate with the clinical severity of ASD. By analyzing a cohort of patients with sporadic epilepsy  
6 we are able to disentangle seizure-associated and primary ASD-associated gene expression  
7 changes. The ASD-specific genes highly correlated with clinical phenotypes represent high  
8 priority therapeutic targets for ASD. Future studies involving larger patient cohorts including  
9 whole exome sequencing and improved single-cell technologies will allow for more precise  
10 identification of ASD-driven molecular changes and their association with deleterious genetic  
11 variants.

12 Our data describing transcriptomic changes across cortical cell types in ASD, highlighting the most  
13 implicated cell types, genes, and pathways can be interrogated through an interactive web browser:  
14 <https://cells.ucsc.edu/dev/?ds=autism> (11).

15

1 **References and Notes:**

- 2 1. I. Voineagu et al., Transcriptomic analysis of autistic brain reveals convergent molecular  
3 pathology. *Nature* 474, 380-384 (2011).
- 4 2. N. N. Parikshak et al., Genome-wide changes in lncRNA, splicing, and regional gene  
5 expression patterns in autism. *Nature* 540, 423-427 (2016).
- 6 3. S. Gupta et al., Transcriptome analysis reveals dysregulation of innate immune response  
7 genes and neuronal activity-dependent genes in autism. *Nature communications* 5, 5748 (2014).
- 8 4. B. B. Lake et al., Neuronal subtypes and diversity revealed by single-nucleus RNA  
9 sequencing of the human brain. *Science (New York, N.Y.)* 352, 1586-1590 (2016).
- 10 5. B. B. Lake et al., Integrative single-cell analysis of transcriptional and epigenetic states in  
11 the human adult brain. *Nat Biotechnol* 36, 70-80 (2018).
- 12 6. B. S. Abrahams et al., SFARI Gene 2.0: a community-driven knowledgebase for the autism  
13 spectrum disorders (ASDs). *Molecular Autism* 4, 36-36 (2013).
- 14 7. S. J. Sanders et al., Insights into Autism Spectrum Disorder Genomic Architecture and  
15 Biology from 71 Risk Loci. *Neuron* 87, 1215-1233 (2015).
- 16 8. F. K. Satterstrom et al., Novel genes for autism implicate both excitatory and inhibitory  
17 cell lineages in risk. *bioRxiv*, 484113 (2018).
- 18 9. N. N. Parikshak et al., Integrative functional genomic analyses implicate specific molecular  
19 pathways and circuits in autism. *Cell* 155, 1008-1021 (2013).

- 1 10. A. J. Willsey et al., Coexpression networks implicate human midfetal deep cortical  
2 projection neurons in the pathogenesis of autism. *Cell* 155, 997-1007 (2013).
- 3 11. T. J. Nowakowski et al., Spatiotemporal gene expression trajectories reveal developmental  
4 hierarchies of the human cortex. *Science* 358, 1318-1323 (2017).
- 5 12. A. Au - Matevossian, S. Au - Akbarian, Neuronal Nuclei Isolation from Human  
6 Postmortem Brain Tissue. *JoVE*, e914 (2008).
- 7 13. N. Habib et al., Massively parallel single-nucleus RNA-seq with DroNc-seq. *Nature*  
8 *methods* 14, 955-958 (2017).
- 9 14. K. Shekhar et al., Comprehensive Classification of Retinal Bipolar Neurons by Single-Cell  
10 Transcriptomics. *Cell* 166, 1308-1323.e1330 (2016).
- 11 15. L. v. d. Maaten, G. Hinton, Visualizing data using t-SNE. *Journal of Machine Learning*  
12 *Research* 9, 2579-2605 (2008).
- 13 16. T. Stuart et al., Comprehensive integration of single cell data. *bioRxiv*, 460147 (2018).
- 14 17. R. Satija, J. A. Farrell, D. Gennert, A. F. Schier, A. Regev, Spatial reconstruction of single-  
15 cell gene expression data. *Nature Biotechnology* 33, 495 (2015).
- 16 18. G. Finak et al., MAST: a flexible statistical framework for assessing transcriptional  
17 changes and characterizing heterogeneity in single-cell RNA sequencing data. *Genome biology*  
18 16, (2015).
- 19 19. M. Martin, Cutadapt removes adapter sequences from high-throughput sequencing reads.

- 1 EMBnet.journal; Vol 17, No 1: Next Generation Sequencing Data AnalysisDO -  
2 10.14806/ej.17.1.200, (2011).
- 3 20. D. Kim, B. Langmead, S. L. Salzberg, HISAT: a fast spliced aligner with low memory  
4 requirements. *Nature Methods* 12, 357 (2015).
- 5 21. Y. Liao, G. K. Smyth, W. Shi, featureCounts: an efficient general purpose program for  
6 assigning sequence reads to genomic features. *Bioinformatics* 30, 923-930 (2014).
- 7 22. D. Bates, M. Mächler, B. Bolker, S. Walker, Fitting Linear Mixed-Effects Models Using  
8 lme4. *Journal of Statistical Software*; Vol 1, Issue 1 (2015), (2015).
- 9 23. H. Mi, A. Muruganujan, J. T. Casagrande, P. D. Thomas, Large-scale gene function  
10 analysis with the PANTHER classification system. *Nature protocols* 8, 1551-1566 (2013).
- 11 24. M. A. DePristo et al., A framework for variation discovery and genotyping using next-  
12 generation DNA sequencing data. *Nat Genet* 43, 491-498 (2011).
- 13 25. A. McKenna et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing  
14 next-generation DNA sequencing data. *Genome Res* 20, 1297-1303 (2010).
- 15 26. T. S. Lee et al., Gene expression in temporal lobe epilepsy is consistent with increased  
16 release of glutamate by astrocytes. *Mol Med* 13, 1-13 (2007).

17

1 **Acknowledgments**

2 **Funding:** This work was supported by Simons Foundation Pilot award 515488 and NIH NIMH  
3 award 1U01MH114825-01 to Arnold Kriegstein. D.V. was supported by Quantitative Biosciences  
4 Institute's BOLD & BASIC Fellowship. L.S. was supported by postdoctoral fellowships from the  
5 German Research Foundation (DFG, SCHI 1330/1-1) and the National Multiple Sclerosis Society  
6 Dave Tomlinson Research Fund (NMSS, FG-1607-25111). Y.P. was supported by Gruss Lipper  
7 postdoctoral fellowship. S.M. was supported by postdoctoral fellowships from the European  
8 Molecular Biology Organization (EMBO, ALTF\_393-2015) and the German Research Foundation  
9 (DFG, MA 7374/1-1). D.H.R. acknowledges the NINDS (P01NS08351) and the Wellcome Trust  
10 for support. A.B. was supported by the postdoctoral fellowship F32NS103266 from the NIH.

11 **Author contributions:** D.V.: Conceptualization, Data curation, Formal analysis, Funding  
12 acquisition, Investigation, Methodology, Software, Writing – original draft; L.S.:  
13 Conceptualization, Investigation, Methodology, Writing – review & editing; D.J.: Investigation,  
14 Writing – review & editing; M.H.: Software, Writing – review & editing; Y.P.: Investigation,  
15 Methodology; S.M.: Investigation, Writing – review & editing; A.B.: Methodology, Software,  
16 Writing – review & editing; N.G.: Investigation, Writing – review & editing; D.R.: Data curation,  
17 Writing – review & editing; A.K.: Conceptualization, Supervision, Funding acquisition, Data  
18 curation, Writing – review & editing. **Competing interests:** Authors declare no competing  
19 interests. **Data and materials availability:** All data are available in the Supplement; raw data are  
20 available through the Sequence Read Archive, accession number SRP132816. Analyzed data and  
21 visualization available at <https://cells.ucsc.edu/dev/?ds=autism>. We thank NIH NeuroBioBank,  
22 University of Maryland School of Medicine Brain and Tissue Bank and especially Alexandra  
23 LeFevre and Olivia Spicer for help with obtaining tissue samples and sample information. We



1 would like to thank Dr. Stephan Sanders, Dr. Neelroop Parikshak, Dr. Evan Eichler, Dr. Matthew  
2 State for insightful comments on the manuscript.

3 **Supplementary Materials:**

4 Materials and Methods

5 Supplementary Text

6 Figures S1-S6

7 Data S1-S5

8 References (12-26)

9



1

2

Supplementary Materials for

3

**Single-Cell Genomics Identifies Cell Type-Specific**

4

**Molecular Changes in Autism**

5

Dmitry Velmeshev, Lucas Schirmer, Diane Jung, Maximilian Haeussler, Yonatan Perez, Simone Mayer, Aparna

6

Bhaduri, Nitasha Goyal, David H. Rowitch and Arnold R. Kriegstein

7

Correspondence to: [Arnold.Kriegstein@ucsf.edu](mailto:Arnold.Kriegstein@ucsf.edu) or [dmitry.velmeshev@ucsf.edu](mailto:dmitry.velmeshev@ucsf.edu)

8

9

**This PDF file includes:**

10

Materials and Methods

11

Supplementary Text

12

Figs. S1 to S6

13

Data S1 to S5

14

References 12-26

15

16

## 1 **Materials and Methods:**

### 2 Processing of brain tissue samples

3 De-identified snap-frozen post-mortem tissue samples from ASD and epilepsy patients and control  
4 donors without neurological disorders were obtained from the University of Maryland Brain Bank  
5 through the NIH NeuroBioBank. 41 tissue samples from 16 control subjects and 15 ASD patients  
6 were used; in addition, we analyzed 8 sporadic epilepsy (epilepsy-not otherwise specified) patients  
7 and age- and sex-matched neurologically normal controls. We utilized tissue from the prefrontal  
8 cortex (PFC) and the anterior cingulate cortex (ACC). For 20 individuals (14 ASD and 6 controls),  
9 paired PFC and ACC samples were analyzed. Cortical samples encompassing the entire span of  
10 the cortex were sectioned on a cryostat to collect 100 um sections for total RNA isolation and  
11 nuclei isolation. In case of the presence of subcortical white matter, white matter was dissected out  
12 prior to collecting sections containing all layers of the cortical grey matter.

13 Total RNA from ~10 mg of collected tissue was isolated and used to perform RNA integrity  
14 analysis on the Agilent 2100 Bioanalyzer using RNA Pico Chip assay. Only samples with RNA  
15 integrity number (RIN) >6.5 were used to perform nuclei isolation and single-nucleus RNA  
16 sequencing (snRNA-seq).

### 17 Nuclei isolation and snRNA-seq on the 10X Genomics platform

18 Matched control and ASD samples were processed in the same nuclear isolation batch to minimize  
19 potential batch effects. 40 mg of sectioned brain tissue was homogenized in 5 mL of RNAase-free  
20 lysis buffer (12) (0.32M sucrose, 5 mM CaCl<sub>2</sub>, 3 mM MgAc<sub>2</sub>, 0.1 mM EDTA, 10 mM Tris-HCl,  
21 1 mM DTT, 0.1% Triton X-100 in DEPC-treated water) using glass dounce homogenizer (Thomas

1 Scientific, Cat # 3431D76) on ice. The homogenate was loaded into a 30 mL thick polycarbonate  
2 ultracentrifuge tube (Beckman Coulter, Cat # 355631). 9 mL of sucrose solution (REF) (1.8 M  
3 sucrose, 3 mM MgAc<sub>2</sub>, 1 mM DTT, 10 mM Tris-HCl in DEPC-treated water) was added to the  
4 bottom of the tube with the homogenate and centrifuged at 107,000 g for 2.5 hours at 4°C.  
5 Supernatant was aspirated, and the nuclei containing pellet was incubated in 250 uL of DEPC-  
6 treated water-based PBS for 20 min on ice before resuspending the pellet. The nuclear suspension  
7 was filtered twice through a 30 um cell strainer. Nuclei were counted using a hemocytometer and  
8 diluted to 2,000 nuclei/uL before performing single-nuclei capture (13) on the 10X Genomics  
9 Single-Cell 3' system. Target capture of 3,000 nuclei per sample was used; the 10X capture and  
10 library preparation protocol was used without modification. Matched control and ASD samples  
11 were loaded on the same 10X chip to minimize potential batch effects. Single-nucleus libraries  
12 from individual samples were pooled and sequenced on the NovaSeq 6000 machine (average depth  
13 70,000 reads/nucleus).

#### 14 snRNA-seq data processing with 10X Genomics CellRanger software and data filtering

15 For library demultiplexing, fastq file generation and read alignment and UMI quantification,  
16 CellRanger software v 1.3.1 was used. CellRanger was used with default parameters, except for  
17 using pre-mRNA reference file (ENSEMBL GRCh38) to insure capturing intronic reads  
18 originating from pre-mRNA transcripts abundant in the nuclear fraction.

19 Individual expression matrices containing numbers of Unique molecular identifiers (UMIs) per  
20 nucleus per gene were filtered to retain nuclei with at least 500 genes expressed and less than 5%  
21 of total UMIs originating from mitochondrial and ribosomal RNAs. Mitochondrial RNA genes  
22 were filtered out as well to exclude transcripts coming from outside the nucleus to avoid biases

1 introduced by nuclear isolation and ultracentrifugation. Individual matrices were combined, UMIs  
2 were normalized to the total UMIs per nucleus and log transformed.

### 3 Species mixing experiments for estimating mutiplet rates

4 To estimate rates of capturing more than one nucleus on the 10X Genomics platform, we isolated  
5 nuclei from either human or mouse cortical samples and performed nuclear capture and snRNA-  
6 seq of 1:1 human:mouse nucleus mixtures and two different nuclei concentrations. CellRanger was  
7 used to perform multigenome analysis and estimate effective multiplet rates.

### 8 Dimensionality reduction, clustering and t-SNE visualization

9 Nuclei for all ASD and control subjects and from both the PFC and ACC were used for clustering.  
10 Filtered (containing genes expressed in more than five cells) log-transformed UMI matrix was  
11 used to perform truncated singular value decomposition (SVD) with  $k=50$ . Scree plot was  
12 generated to select the number of significant principle components (PCs) by localizing the last PC  
13 before the explained variance reaches plateau. In order to ensure that clustering was not driven by  
14 batch effects, we explored the correlation of the PC scores with the experimental batch label  
15 (combined 10x capture batch and sequencing batch). We set a threshold of Pearsons correlation  
16 coefficient ( $r$ ) to be at least 0.2 to consider a PC to be correlated with the batch label. At this cutoff,  
17 three out of 16 significant PCs were removed. The resulting PCs were used to calculate Jaccard-  
18 weighted nearest neighbor distances; the number of nearest neighbors was assigned to root square  
19 of number of nuclei. The resulting graph with Jaccard-weighted edges was used to perform  
20 Louvain clustering (14). To visualize nuclear transcriptomic profiles in two-dimensional space, t-  
21 distributed stochastic neighbor embedding (t-SNE) (15) was performed with the selected PCs and

1 perplexity=40 and combined with cluster annotations.

2 To verify the stability of the observed clusters, we additionally performed clustering using Seurat  
3 v.3 (16, 17). The default Seurat pipeline was utilized, except for the following: scree plot was used  
4 to select significant PCs (selecting 15 PCs), and k for nearest neighbor calculation was set to root  
5 square of number of nuclei. Seurat was able to produce clusters similar to the ones originally  
6 observed. Seurat clusters were not driven by batch effects despite the fact no explicit batch effect  
7 reduction was utilized in Seurat analysis. In order to compare the cell type assignment between the  
8 original clusters and using Seurat, the percentage of cells from each original cluster belonging to  
9 one of Seurat clusters was calculated.

#### 10 Cell type annotation and quantification of regional and individual contribution to cell types

11 Cell types were annotated based on expression of known marker genes visualized on the t-SNE  
12 plot and by performing unbiased gene marker analysis. For the latter, MAST (18) was used to  
13 perform differential gene expression analysis by comparing nuclei in each cluster to the rest of the  
14 nuclear profiles. Genes with  $FDR < 0.05$  and log fold change of 1 or more were selected as cell type  
15 markers. We originally recovered a single cluster of astrocytes. In order to test whether we could  
16 differentiate between the two well-described subtypes of astrocytes, protoplasmic and fibrous  
17 astrocytes, we performed a semi-supervised sub clustering. First, we used a subset of our dataset  
18 that included all astrocyte nuclear profiles and only the genes that were identified as astrocyte  
19 markers as described above ( $FDR < 0.05$  and  $FC \geq 1$  when compared to all other cells combined).  
20 Then, we performed PCA dimensionality reduction of the astrocytes dataset and selected  
21 significant PCs using scree plot method. Then we used partitioning around medoids (PAM) with  
22  $k=2$  to bi-cluster the astrocytes based on the marker genes. This generated one cluster with

1 relatively high expression of fibrous astrocyte markers, such as GFAP and TNC, and another  
2 cluster expressing higher levels of markers of protoplasmic astrocytes, such as SLC1A2.

3 To gain insight into the regional enrichment of cell types, the number of nuclei in each cluster was  
4 normalized to the total number of nuclei captured from each region. The same normalization  
5 procedure was performed to quantify the number of nuclei per cluster coming from each individual  
6 and control and ASD group.

### 7 Differential gene expression analysis

8 To identify genes differentially expressed in ASD compared to control in each cell type, MAST  
9 was used to perform zero-inflated regression analysis by fitting a linear mixed model (LMM). We  
10 used a combined dataset that included nuclei from both cortical regions (PFC and ACC). LMM  
11 included age, sex, cortical region, RIN and post-mortem interval, as well as 10X capture and  
12 sequencing batch and per-cell ribosomal RNA fraction. We accounted for the fact that multiple  
13 nuclei were captured from each individual using a hierarchical model design. The following model  
14 was fit with MAST:

```
15 zlm(~diagnosis + (1|ind) + cngeneson + age + sex + RIN + PMI + region + Capbatch + Seqbatch  
16 + ribo_perc, sca, method = "glmer", ebayes = F, silent=T)
```

17 Where cngeneson is gene detection rate (factor recommended in MAST tutorial), Capbatch is 10X  
18 capture batch, Seqbatch is sequencing batch, ind is individual label, RIN is RNA integrity number,  
19 PMI is post-mortem interval and ribo\_perc is ribosomal RNA fraction.

20 To identify genes differentially expressed due to the disease effect, likelihood ratio test (LRT) was

1 performed by comparing the model with and without the diagnosis factor. Genes with fold change  
2 of expression of at least 0.14 (10% difference) and  $FDR < 0.05$  were selected as differentially  
3 expressed. In addition, we calculated sample-level fold change of gene expression by aggregating  
4 nuclear expression profiles in each sample and calculating ASD/Control fold changes based on  
5 gene expression in samples. For most genes, cell and sample-levels fold changes were concordant,  
6 and we further filtered genes with at least 10% concordant change in gene expression on the sample  
7 level.

#### 8 Correlation of individual-level fold changes and ADI-R scores

9 To estimate individual-level fold changes, we calculated fold change of gene expression using  
10 MAST and comparing each ASD case to the combined control group. To acquire the combined  
11 score reflecting the clinical severity of ASD-associated behavioral manifestations, we first  
12 retrieved individual ADI-R scores (categories A, B-verbal, B-nonverbal, C and D) and ranked the  
13 scores for all ASD patients within each category. By calculating the sum of individual ranks, we  
14 acquired the combined clinical score. We then calculated Pearson's correlation coefficient and  
15 associated p value by correlating the combined clinical scores with individual-level fold changes  
16 of DEGs. We determined the meta Pearson's p value for each cell type by combining all DEGs in  
17 a specific cell type using Fisher's method. Meta p value was used as approximation of how well  
18 the changes in a given cell type correlate with clinical severity of ASD.

#### 19 Region-specific clustering and differential gene expression analysis to identify region-specific 20 DEGs

21 To perform clustering in each of the cortical regions separately, the same workflow as for the



1 combined dataset was used: normalized and log transformed UMI counts from each region  
2 separately were used for PCA, then significant PCs were determined based on scree plot (resulting  
3 in 17 PCs for both the PFC and ACC), and PCs correlating with experimental batches were  
4 removed (removing 6 PCs for the PFC and 2 PCs for the ACC). Selected PCs were used to  
5 calculate nearest neighbor distances, which were then Jaccard weighted and utilized to perform  
6 Louvain clustering. In both the PFC and ACC, astrocyte cluster was subclustered into two  
7 clustered as described above. In addition, in the PFC L2/3 and L5/6-CC originally clustered  
8 together and were subclustered using the same approach as for astrocytes.

9 To identify genes differentially expressed in ASD compared to control in each cell type in a region-  
10 specific manner, we used MAST and the same regression model as for the combined dataset, with  
11 the exception of the region factor, which was removed from the formula. Then, we looked for  
12 genes that had log-transformed fold change of expression of at least 0.14 (10% difference) and  
13  $FDR < 0.05$  in one region (PFC or ACC) but less than 5% difference in expression ASD vs control  
14 and  $FDR > 0.5$  in the other region. This allowed us to identify genes that were dysregulated in only  
15 the PFC or ACC but not both regions.

#### 16 Downsampling analysis to estimate degree of ASD-associated gene dysregulation across cell types

17 To calculate the number of ASD-associated DEGs across cell types normalized by number of cells  
18 in each cluster, we randomly drew 1,900 nuclei from each cell type before performing differential  
19 expression analysis. This analysis was repeated across 10 permutations, and average number of  
20 DEGs for each cell type was estimated.

#### 21 Bulk RNA sequencing analysis

1 Bulk tissue RNA was extracted from the same samples used for snRNA-seq. RNA was extracted  
2 from adjacent frozen tissue sections obtained during the same sectioning session as sections for  
3 nuclear isolation. RNA was isolated with a hybrid Trizol-Qiagen column protocol, polyadenylated  
4 RNA was purified (New England Biolabs, E7490L) and used to construct directional RNA-seq  
5 libraries (New England Biolabs, E7420L). All samples were processed and sequenced in a single  
6 batch. Libraries were sequenced on the Illumina NovaSeq 6000 machine at average depth of  
7 100,000 150 bp paired-end reads per sample. Reads were trimmed off adapters with TrimGalore!  
8 (19) and aligned to the genome using HISAT2 (20), with average alignment rate of 90%. To assess  
9 sequencing data quality, fastQC was used to generate sequencing quality metrics reports for each  
10 sample. Counts were summarized with featureCounts (21) and normalized to obtain fragments per  
11 kilobase per million reads mapped (FPKM). Log transformed FPKM were used to perform  
12 different expression analysis using lme4 R package (22) and the following regression model:

13  $\text{expression} \sim \text{Diagnosis} + (1|\text{Individual}) + \text{region} + \text{age} + \text{sex} + \text{RIN} + \text{PMI}$

14 Same parameters as for snRNA-seq were used to determine differentially expressed genes:  
15  $\text{FDR} > 0.05$  and at least 10% change in gene expression level.

16 To correlate bulk tissue mRNA levels with nuclear RNA levels, we bulkized snRNA-seq data by  
17 aggregating all nuclear profiles by sample and compared bulk mRNA FPKMs to normalized  
18 bulkized UMIs.

19 Statistical overrepresentation test for Gene Ontology (GO) terms

20 PANTHER (23) was used to perform statistical overrepresentation test for DEGs from each  
21 cluster. All genes tested for differential expression in a given cluster were used as the background

1 and GO Biological Processes ontology was used. Binomial test with FDR correction was used,  
2 and processes with  $FDR < 0.05$  were considered and sorted by FDR.

### 3 Hypergeometric testing

4 To estimate the significance of overlap of two gene lists, we performed hypergeometric testing.  
5 To estimate overlap of ASD genetic risk factors with DEGs in each cell type, the list of DEGs in  
6 a given cell type was used as the sample, and list of all genes expressed in the cell type as the  
7 population list. These lists were overlapped with all genes in the SFARI Gene Module database  
8 having evidence of genetic association (rare single gene mutation, genetic association or  
9 syndromic) with ASD or genes from Sanders et al. and Satterstrom et al studies. Hypergeometric  
10 p values were FDR-corrected using Benjamini and Hochberg procedures.

### 11 Deconvolution of bulk RNA-seq data using cell type signatures and WGCNA gene module 12 memberships

13 In order to leverage the existing bulk RNA-seq data from post-mortem ASD brain tissue, we  
14 obtained data from the largest bulk RNA-seq study of ASD (3), that analyzed samples from 48  
15 ASD individuals and 49 controls. For each gene expressed in the bulk RNA-seq dataset, we  
16 obtained information on its membership in modules of co-expressed genes identified using  
17 Weighted Gene Co-expression Network Analysis (WGCNA). We then calculated enrichment of  
18 each module for the cell type markers identified in our snRNA-seq dataset (data S3;  
19 hypergeometric test). The resulting p values for enrichment of each module across the cell types  
20 in our dataset were corrected for multiple comparisons and used to identify cell types clearly  
21 enriched for one module. We then retrieved the genes differentially expressed in bulk ASD tissue

1 and belonging to such cell type-specific modules and performed gene ontology analysis to identify  
2 enriched cellular pathways.

### 3 Analysis of gene expression changes in each ASD individual

4 In order to identify genes that are differentially expressed in specific ASD patients in each cell  
5 type, for each cluster we compared cells of each cell type from each patient to the combined cells  
6 from all control individuals. Since cells from a single ASD patient were considered for this  
7 analysis, we utilized a generalized linear model with the same continuous fixed-effect factors as  
8 for the LMM approach but dropping the random-effect individual label:

```
9 form=as.formula("~diagnosis + cngeneson + age + RIN + PMI + ribo_perc + Capbatch + Seqbatch  
10 + region + sex")
```

11 We then applied the same filters as for combined gene expression analysis ( $FDR < 0.05$ ;  $FC \geq 10\%$ )  
12 to identify genes differentially expressed in each patient compared to control. Genes were  
13 considered as differentially expressed if they were: differentially expressed in a single patient OR  
14 differentially expressed in multiple patients and changed in the same direction (up- or  
15 downregulated) across all patients with a significant change. Genes dysregulated in a concordant  
16 manner in at least five ASD patients were included in Data S4.

17 To estimate the relative contribution of differentially expressed genes by each cell type in a given  
18 ASD patient, we downsampled the cells for that patient to the same number across all clusters  
19 before performing differential expression analysis. We performed this procedure 10 times for each  
20 patient and cell type and calculated the median number of DEGs in each cell type and ASD patient.  
21 We then calculated the percentage of all patient DEGs that are contributed to by a given cell type.

## 1 Whole exome sequencing and data analysis

2 DNA Extraction from snap-frozen post-mortem tissue samples of ASD patients was done using  
3 the DNeasy Blood and Tissue kit according to the manufacturer's instructions (Qiagen, Cat #  
4 69504). Exome libraries were prepared using the SeqCap EZ Human Exome v3 kit and sequenced  
5 on the Illumina NovaSeq 6000 platform at mean coverage depth of 100 reads per base with 150  
6 bp paired-end reads protocol. Sequencing read alignment, variant calling and annotation were  
7 performed using GATK pipeline (24-25) using the standard whole-exome sequencing analysis  
8 workflow from the Broad Institute ([https://github.com/gatk-workflows/gatk4-exome-analysis-](https://github.com/gatk-workflows/gatk4-exome-analysis-pipeline)  
9 [pipeline](https://github.com/gatk-workflows/gatk4-exome-analysis-pipeline)), the hg38 reference and intervals file specific for SeqCap EZ Human Exome v3. By-  
10 sample GVCF files produced by GATK were further analyzed using Ingenuity® Variant  
11 Analysis™ software (IVA, QIAGEN Redwood City). To explore possible contribution of rare  
12 genetic variants to the disease phenotype we focused on variants which survived a meticulous  
13 filtering cascade. In our analysis, we kept variants with call quality of at least 20.0 and outside top  
14 5.0% most exonically variable 100base windows in healthy public genomes (1000 genomes). We  
15 excluded variants which are observed with an allele frequency  $\geq 1.0\%$  of the genomes in the 1000  
16 genomes project, the NHLBI ESP exomes (All), the Exome Aggregation Consortium (ExAC) or  
17 the Genome Aggregation Database (gnomAD) unless established as pathogenic common variant.  
18 We kept variants (up to 20 bases into intron) that are predicted to have a deleterious effect upon  
19 protein coding sequences (e.g. Frameshift, in-frame indel, stop codon change, missense, predicted  
20 to disrupt splicing by MaxEntScan or within 2 bases into intron) and variants which are  
21 experimentally observed to be pathogenic, possibly pathogenic or Disease-associated according to  
22 HGMD, clinically relevant variants from CentoMD and variants known or predicted to affect  
23 autism (biological context filter by IVA). following our filtering strategy, a curated table with

1 relevant variants was generated for each ASD patient (data S5).

## 2 Histology and immunohistochemistry

3 Snap-frozen human brain tissue blocks were stored at -80°C. 16µm-cryosections were collected  
4 on superfrost slides (VWR) using a CM3050S cryostat (Leica) and fixed in 4% PFA at room  
5 temperature (RT). For immunohistochemistry, sections were blocked in 0.1M PBS/0.1% Triton  
6 X-100/ 10% goat/horse/donkey sera for 30min at RT. Primary antibody incubations were carried  
7 out overnight at 4°C. For chromogenic staining, upon washing in 0.1M PBS, cryosections were  
8 incubated with biotinylated secondary IgG antibodies (1:500, Thermo Fisher) followed by avidin-  
9 biotin complex for 1-hour incubation (1:500, Vector) and subsequent color revelation using  
10 diaminobenzidine according to the manufacturer's recommendations (DAB, Dako). For  
11 immunofluorescence, Alexa fluochrome-tagged secondary IgG antibodies (1:500, Thermo Fisher)  
12 were used for primary antibody detection. Secondary antibodies were diluted in 0.1M PSB/ 0.1%  
13 Triton X-100 for 2 hours at RT. Slides with fluorescent antibodies were mounted with DAPI  
14 Fluoromount-G (SouthernBiotech). For chromogenic IHC, counterstaining with hematoxylin was  
15 carried out. Negative control sections without primary antibodies were processed in parallel.

16 The following antibodies were used for immunohistochemistry: rat anti-GFAP (clone 2.2B10, 13-  
17 0300, Invitrogen, 1:200), goat anti-GLT-1 (AB1783, Millipore Sigma, 1:500).

## 18 Single-molecule *in situ* RNA hybridization

19 Single molecule *in situ* hybridization was performed according to the RNAscope manuals (2.5  
20 manual assay red chromogenic and duplex chromogenic). Sequences of target probes,  
21 preamplifier, amplifier, and label probe are proprietary and commercially available (Advanced

1 Cell Diagnostics (ACD), Hayward, CA). Typically, the probes contain 20 ZZ probe pairs (approx.  
2 50 bp/pair) covering 1000bp. Here, we used probes against human *CST3*, *NRGN* (both C1 channel)  
3 and *SYT1* (C2 channel). After red chromogenic single-molecule in situ hybridization, we  
4 performed immunohistochemistry using either a biotinylated chromogenic (DAB) based detection  
5 system or applied Alexa-dye conjugated secondary antibodies with DAPI counterstain of nuclei  
6 (see above). After chromogenic in situ hybridization assays we performed hematoxylin  
7 counterstain of nuclei.

### 8 Image acquisition and analysis

9 Fluorescent images were taken using a Leica TCS SP8 laser confocal microscope with 10x or 20x  
10 objectives; all fluorescent pictures are z-stack confocal images. Bright field images were acquired  
11 on a Zeiss Axio Imager 2 microscope. Images were processed using Fiji ImageJ software and  
12 exported to Illustrator vector-based software (Adobe) for figure generation.

### 13 Data availability

14 Raw RNA-seq and exome sequencing data are available at the SRA accession SRP132816.

15 We offer an interactive web browser to browse cell types, cell type markers and ASD-associated  
16 gene expression changes in each cell type through the UCSC Cluster Browser:

17 <https://cells.ucsc.edu/dev/?ds=autism>

18

## 1 **Supplementary Text**

### 2 **Region-specific analysis of ASD-associated gene expression changes**

3 Since the distribution of cells from the PFC and ACC in the ASD and Control groups was not  
4 uniform (1:1.6 in ASD compared to 1:1.35 in Control); we performed additional clustering of PFC  
5 and ACC cells separately to validate the increased number of protoplasmic astrocytes in ASD (fig.  
6 S2 A to C). Based on analysis of region-specific DEGs (Materials and Methods), we identified  
7 206 regional DEGs (70 in the PFC and 136 in the ACC) (fig. S4C). These genes were differentially  
8 expressed in the ASD specifically in one of the two regions analyzed. Gene Ontology analysis  
9 suggested that they are enriched in processes associated with neuronal migration, differentiation,  
10 apoptosis, and neurite outgrowth (fig. S4D). Interestingly, synaptic signaling was not one of the  
11 enriched GO terms; however, we observed individual synaptic genes that are preferentially  
12 dysregulated in the PFC or ACC (fig. S4, E to G). Such genes included *CAMK2B* and *SYNGRI* in  
13 L2/3, *SYP* in IN-PV and *RAB3A* in IN-VIP. *ARID1B*, a prominent ASD risk gene, was upregulated  
14 in PFC L4 neurons but not in ACC neurons (fig S4F).

### 15 **Analysis of differentially expressed genes shared between ASD and epilepsy patients**

16 We analyzed single-nuclei profiles of post-mortem tissue of patients with sporadic epilepsy and  
17 compared the cell type-specific gene expression profiles to matched controls. We identified a  
18 number of differentially expressed genes (Data S4; fig. S6); many epilepsy DEGs associated  
19 pathways were previously reported in bulk gene expression study of post-mortem brain tissue of  
20 epilepsy patients (26). In order to assess whether DEGs common between the ASD and epilepsy  
21 cohorts were among top ASD dysregulated genes, we calculated the median q value for all DEGs



1 and DEGs common between ASD and epilepsy in all cell types. This analysis produced a q value  
2 of 0.021 for all DEGs and 0.02 for common ASD/epilepsy DEGs. When only L2/3 DEGs were  
3 considered, the corresponding q values were 0.0087 for ASD and 0.0086 for common  
4 ASD/epilepsy DEGs. Therefore, we conclude that genes commonly dysregulated in epilepsy are  
5 not among the top ASD dysregulated genes.

## 6 **Deconvolution analysis of bulk RNA-seq data**

7 In order to leverage our single-cell analysis to deconvolute bulk RNA-seq data from ASD patient  
8 cortical tissue, we utilized a published dataset from the Geschwind lab (3), which sequenced the  
9 largest cohort of ASD samples to date (48 ASD individuals, 49 controls). For each gene from the  
10 Parikshak dataset, we retrieved the module assignment based on Weighted Gene Coexpression  
11 Network Analysis (WGCNA) performed in the original dataset. WGCNA uses the principle of co-  
12 expression of genes that belong to the same cellular pathway or cell type in order to group genes  
13 into co-expression modules and deconvolute bulk gene expression data. Co-expression modules  
14 often correspond to cell types; therefore, we used the cluster marker information from our dataset  
15 (data S3) to identify modules that are highly enriched for markers of the cell types we identified  
16 using snRNA-seq (Methods). We were able to identify three WGCNA modules that clearly  
17 correspond to a specific cell type: green (astrocytes, both AST-PP and AST-FB), pink (microglia)  
18 and blue (oligodendrocytes) (figure S6B). Additionally, the yellow module was highly enriched  
19 for markers of L2/3 neurons, but also contained markers of other neuronal subtypes, suggesting  
20 that discerning between neuronal subtypes is challenging using bulk RNA-seq data and WGCNA.  
21 We next retrieved the list of differentially expressed genes for the four WGCNA modules that  
22 were associated with specific cell types in our dataset (total of 217 DEGs) and annotated them

1 based on the closest cell type according to the analysis detailed above. These insights into cell  
2 type-specific transcriptional changes based on bulk data deconvolution are now reported in data  
3 S4. Gene ontology analysis of the differentially expressed genes in the green module (strongly  
4 associated with an astrocyte signature) suggested an activated state of astrocytes and glycogenesis  
5 (figure S6C), validating our approach to deconvolution of bulk tissue data and supporting our  
6 observation of an increased number of astrocytes in the neocortex of ASD patients.

### 7 **Individual-level analysis of ASD gene expression changes**

8 We next sought to investigate whether ASD-associated transcriptional changes affected the same  
9 or different cell types in each patient. First, we aimed to estimate the cell types that were most  
10 affected in each ASD patient. For each patient, we downsampled each cell type to the same number  
11 of cells and performed differential expression analysis by comparing cells from a single ASD  
12 patient to the cells of the same type from all control samples using a regression model to control  
13 for covariates, such as age and PMI (Methods). We performed this analysis over ten permutations  
14 and calculated the average number of differentially expressed genes (DEGs) for all the cell types  
15 in each ASD patient. For each patient, we then estimated the percentage of DEGs contributed by  
16 each cell type. We identified five cell types contributing most DEGs in each ASD patient (fig.  
17 S6A). We observed that L5/6-CC neurons (deep-layer cortico-cortical projection neurons) and  
18 L2/3 neurons were the most affected cell types across multiple patients with ASD. However, L5/6-  
19 CC neurons were not particularly enriched for ASD-associated DEGs when cells from all ASD  
20 patients were compared to the control group (Figure 2I), suggesting that ASD-associated gene  
21 expression changes in this cell type might be highly variable across patients or affect different  
22 genes across individuals. Indeed, we observed relatively more DEGs in L5/6-CC neurons that were


1 unique to a single patient (fig. S6B). Additionally, L2/3 neurons had the largest number of DEGs  
2 shared by multiple ASD patients (fig. S6C; data S4), whereas L5/6-CC neurons had two times  
3 fewer such genes. This suggests that ASD-associated transcriptomic changes can converge on the  
4 same or different genes depending on the cell type.

### 5 **Whole-exome sequencing analysis**

6 In order to test whether samples in our ASD cohort harbored any known genetic variants associated  
7 with autism, epilepsy or other psychiatric or neurodevelopmental disorder, we performed whole-  
8 exome sequencing of the ASD patient DNA (100X coverage). We identified a number of high-  
9 confidence variants associated with neurodevelopmental and psychiatric phenotypes (data S5). As  
10 expected from such a small cohort of patients, these variants were unique to a single patient or  
11 shared by no more than two patients. However, we believe that for future studies coupling single-  
12 cell RNA-seq analysis of post-mortem ASD patient tissue with DNA analysis is a promising  
13 approach that will allow to connect genomic variation with cellular phenotypes in ASD.

14 In order to investigate the potential impact of genetic variants on the gene expression in each ASD  
15 patient, we focused on variants in the promoter sequences or frameshift/stop gain variants of the  
16 genes that are also differentially expressed in a given ASD individual compared to the combined  
17 group. We filtered any upregulated genes or genes that are differentially expressed in more than  
18 one cell type but follow a divergent (up and down) pattern of dysregulation. Therefore, we only  
19 retained downregulated genes, reasoning that a polymorphism in a promoter region or causing  
20 frameshift or stop gain is more likely cause downregulation of gene expression through affecting  
21 transcription or nonsense-mediated decay. This analysis identified 41 variants in 28 genes.


1



2

3 **Fig. S1. Sample statistics for experimental groups.** **A)** Comparison of age, sex, RNA integrity number  
4 (RIN) and post-mortem interval (PMI) between control and ASD groups. **B)** Comparisons of number of  
5 genes and transcripts detected per nucleus in control and ASD groups (median across all cell types). **C)**  
6 Multiplet capture rate based on species mixing experiments. **D)** Example of a sequencing saturation curve  
7 reflecting average sequencing saturation for the dataset. **E)** tSNE plot from Fig 1C colored by individual  
8 label, experimental batch, and cortical region to demonstrate absence of clusters dominated by a few  
9 individuals or driven by batch effect. **F)** Number of genes and transcripts detected across cell types. **G)**  
10 Regional composition of cell types. **H-I)** Contribution of control and ASD cells to cell types.





1

2

**Fig. S3. Single-molecule RNA in situ hybridization validation of markers of novel cell types in control**

3

**tissue samples, as well as comparison to bulk RNA-seq data and genetic ASD variants. A)** *In situ* RNA

4

hybridization for NRGN to reveal laminar distribution of NRGN-positive neurons in the prefrontal and

5

anterior cingulate cortex. **B)** Dual RNAscope for NRGN and SYT1 to confirm neuronal identity of NRGN

6

neurons in the ACC. **C)** (left) Levels of GFAP and SLC1A2 (GLT1) in AST-PP and AST-FB cells. (right)

7

Immunohistochemistry of adult human prefrontal cortex for AST-FB marker GFAP and AST-PP marker

8

GLT-1 (SLC1A2). Counterstaining for neurofilament H (SMI32) to delineate layer 1 (L1), layers 2-6 (L2-

9

6) and subcortical white matter (WM). Scale bar 500 um. **D)** Quantification of astrocyte density in cortical

10

layers in the PFC of ASD and control tissue using *in situ* RNA hybridization for CST3, an astrocyte marker

11

(data S3). **E)** Correlation of fold changes in DEGs from Parikshak et al (3) and fold changes based on the

12

bulk RNA-seq analysis of the current sample cohort. **F)** Overlap between DEGs from Parikshak et al and

13

DEGs identified in the current bulk RNA-seq analysis. **G)** Correlation of gene expression levels of bulk

14


tissue mRNA and bulkized nuclear RNA for all samples. **H)** Overlap between cell type-specific DEGs and

15

ASD genetic risk factors with the SFARI database. **I)** Overlap between cell type-specific DEGs and high-


16

confidence ASD genetic risk factors.



**Fig. S4. Additional analysis of cell type-specific and region-specific transcriptional changes in ASD.**

**A)** Processes enriched for neuronal DEGs. **B)** Gene ontology analysis of genes differentially expressed in two or more cell types. **C)** Top genes differentially expressed in IN-VIP interneurons. **D)** Genes upregulated in ASD microglia suggest an activated state. **E)** Top genes differentially expressed in protoplasmic astrocytes in ASD. **F)** Deconvolution of bulk RNA-seq data from cortical ASD samples (3). Colors correspond to modules of genes co-expressed in bulk tissue data. Relative WGCNA co-expression module enrichment in each cell type is depicted by a color bar matching the corresponding WGCNA gene module. **G)** GO analysis of genes differentially expressed in ASD in the green module (highly correlated with astrocyte signatures). **H)** Number of genes dysregulated in each cell type in a region-specific fashion. **I)** Examples of top region-specific DEGs dysregulated in IN-PV and IN-VIP neurons. Fold changes are indicated under the gene names. Star denotes statistically significant change in gene expression between ASD and CNTR in either the PFC or ACC.



1

2


3

4

5

**Fig. S5. Analysis of individual-level variation of gene expression. A-B)** Genes most correlated with clinical severity of ASD and differentially expressed in L2/3 neurons (A) and microglia (B). **C)** Proportion of genes dysregulated in single ASD patients across the cell types analyzed. **D)** Percentage of cell type-specific DEGs that are shared by five or more patients.





**Fig. S6. Analysis of single nucleus RNA-seq data to identify genes differentially expressed in the prefrontal cortex of epilepsy patients.** **A)** Clustering of epilepsy single-cell data and annotation of cell types. Cell type abbreviation used correspond to Figure 1. **B-C)** Distribution of nuclei from individuals and experimental groups among clusters. **D)** Overlap of epilepsy and ASD-associated genes differentially expressed in the PFC by cell type. **E)** Statistical significance of overlap between ASD and sporadic epilepsy PFC DEGs (hypergeometric test). **F)** Expression of neuronal and glial cell type markers. **G)** Gene ontology analysis of PFC DEGs dysregulated in ASD but not sporadic epilepsy. **H)** Overlap between genes dysregulated in sporadic epilepsy and either the ASD subgroup without reported incidence of seizures (N=7) or the ASD subgroup with epilepsy comorbidity (N=8).

1       **Data S1. Sample and clinical information for ASD and epilepsy individuals.**

2       **Data S2. List of captured nuclei and associated metadata for ASD and epilepsy cohorts.**

3       **Data S3. List of cluster-specific and regional gene markers.**

4       **Data S4. List of cell type-specific genes differentially expressed in ASD and epilepsy, as well**  
5       **as region-specific and individual-specific gene expression changes in ASD.**

6       **Data S5. Results of whole-exome sequencing analysis of ASD patients. The first tab includes**  
7       **high-confidence variants, the second tab includes variants that are associated with**  
8       **downregulation of corresponding genes in the same ASD patient when compared to control**  
9       **samples; the other tabs include unfiltered lists of variants for each individual with less**  
10       **confidence in association with ASD, epilepsy or psychiatric disease.**

11

12